Division of Critical Care Medicine, Department of Anesthesiology and Perioperative Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, United States.
Department of Anesthesiology and Perioperative Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA, United States.
Front Immunol. 2022 Jul 4;13:940030. doi: 10.3389/fimmu.2022.940030. eCollection 2022.
Cell-based functional immune-assays may allow for risk stratification of patients with complex, heterogeneous immune disorders such as sepsis. Given the heterogeneity of patient responses and the uncertain immune pathogenesis of sepsis, these assays must first be defined and calibrated in the healthy population.
Our objective was to compare the internal consistency and practicality of two immune assays that may provide data on surrogate markers of the innate and adaptive immune response. We hypothesized that a rapid turnaround, microfluidic-based immune assay (ELLA) would be comparable to a dual-color, enzyme-linked immunospot (ELISpot) assay in identifying tumor necrosis factor (TNF) and interferon (IFN)γ production following whole blood stimulation.
This was a prospective, observational cohort analysis. Whole blood samples from ten healthy, immune-competent volunteers were stimulated for either 4 hours or 18 hours with lipopolysaccharide, anti-CD3/anti-CD28 antibodies, or phorbol 12-myristate 13-acetate with ionomycin to interrogate innate and adaptive immune responses, respectively.
ELLA analysis produced more precise measurement of TNF and IFNγ concentrations as compared with ELISpot, as well as a four- to five-log dynamic range for TNF and IFNγ concentrations, as compared with a two-log dynamic range with ELISpot. Unsupervised clustering accurately predicted the immune stimulant used for 90% of samples analyzed ELLA, as compared with 72% of samples analyzed ELISpot.
We describe, for the first time, a rapid and precise assay for functional interrogation of the innate and adaptive arms of the immune system in healthy volunteers. The advantages of the ELLA microfluidic platform may represent a step forward in generating a point-of-care test with clinical utility, for identifying deranged immune phenotypes in septic patients.
基于细胞的功能免疫分析可用于对复杂、异质性免疫紊乱(如败血症)患者进行风险分层。鉴于患者反应的异质性和败血症不确定的免疫发病机制,这些分析必须首先在健康人群中进行定义和校准。
我们的目的是比较两种免疫分析的内部一致性和实用性,这两种分析可能提供先天和适应性免疫反应替代标志物的数据。我们假设,一种快速周转的、基于微流控的免疫分析(ELLA)与双色酶联免疫斑点(ELISpot)分析在鉴定全血刺激后肿瘤坏死因子(TNF)和干扰素(IFN)γ的产生方面具有可比性。
这是一项前瞻性、观察性队列分析。来自 10 名健康、免疫功能正常的志愿者的全血样本分别用脂多糖、抗 CD3/抗 CD28 抗体或佛波醇 12-肉豆蔻酸 13-乙酸酯加离子霉素刺激 4 小时或 18 小时,分别检测先天和适应性免疫反应。
与 ELISpot 相比,ELLA 分析产生了更精确的 TNF 和 IFNγ浓度测量值,以及 TNF 和 IFNγ浓度的四到五个对数动态范围,而 ELISpot 的动态范围为两个对数。无监督聚类准确预测了 90%的分析样本使用的免疫刺激物ELLA,而 ELISpot 分析的样本仅为 72%。
我们首次描述了一种快速、精确的分析方法,用于功能检测健康志愿者中先天和适应性免疫系统的免疫刺激物。ELLA 微流控平台的优势可能代表了在败血症患者中识别紊乱免疫表型的临床应用方面向前迈进了一步。